Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients (ISS OBS T-004)

This study has been completed.
Italian Ministry of Foreign Affairs - Dir. Gen. for Cooperation and Development
Information provided by (Responsible Party):
Barbara Ensoli, MD, Istituto Superiore di Sanità Identifier:
First received: May 17, 2011
Last updated: March 3, 2016
Last verified: March 2016

Tat is a key HIV regulatory protein produced very early after infection, prior to virus integration, and necessary for viral gene expression, cell-to-cell virus transmission and disease progression. Previous studies in natural HIV infection, indicated that the presence of a Tat-specific immune response correlates with a lower incidence and reduced risk of progression to AIDS as compared to anti-Tat negative individuals suggesting that an immune response to Tat may exert a protective role and control the progression to AIDS in vivo.

On the basis of the above mentioned consideration, the present study was directed at investigating the seroprevalence of anti-Tat antibodies in HIV-infected South African patients.

HIV Infection

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape

Resource links provided by NLM:

Further study details as provided by Istituto Superiore di Sanità:

Primary Outcome Measures:
  • Anti-Tat Antibody Responses [ Time Frame: Up to 14 months ]
    Assessment of serum anti-Tat antibodies. Anti-Tat humoral immune response will include the determination of serum IgM, IgG and IgA antibodies against both clade B- and C-derived Tat proteins and titration of IgM, IgG and IgA anti-Tat antibodies.

Secondary Outcome Measures:
  • Virological status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ]

    HIV viral load and clinical status on anti-Tat+ versus anti-Tat- participants. The effect of ARV treatment non-compliance on viral load in anti-Tat+ versus anti-Tat- participants has been evaluated within the ARV-treated study group on the basis of the relevant available information.

    Hepatitis B, Syphilis, HPV co-infections Assessment.

  • Immunological status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ]
    Assessment of CD4 T cell counts. Exploratory immunological assays may be performed on available residual samples for a more in-depth characterisation of the immune response.

  • Immune activation status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ]
    Assessment of Immune-activation markers on CD4+ and CD8+ T cells (CD25+, CD38+ and HLA-DR+).

Biospecimen Retention:   Samples With DNA
Whole blood, cervical samples

Enrollment: 531
Study Start Date: October 2010
Study Completion Date: July 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Treatment-naive HIV+ subjects
HAART-treated HIV+ subjects

Detailed Description:

This is an observational, cross-sectional study aimed at assessing the frequency, magnitude and quality of the anti-Tat antibody response in both antiretroviral (ARV)-treated and treatment-naïve HIV-infected South African adults, and at exploring the correlation between the presence of anti-Tat antibody response and the immunological status of participants as well as with the presence of co-infections such as HBV, syphilis and HPV (the latter only for female participants).

The study has involved 531 participants and provided important information for the planning, design and conduction of future therapeutic clinical trials with the Tat-based HIV vaccine in South African individuals.

This study is conducted in the frame of the Government-to-Government cooperation program N. AID 8421, funded by the Italian Ministry of Foreign Affairs-Directorate General for Development Cooperation (MAE-DGCS) and jointly implemented by the Italian Istituto Superiore di Sanita' (ISS) and the South African Department of Health in collaboration with the South African AIDS Vaccine Initiative of the Medical Research Council (MRC-SAAVI)


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV positive, ARV-treated and treatment-naïve participants.

Inclusion Criteria:

  • HIV-infected individuals Aged 18-45 years Participants enrolled into the ARV-treated group must have been on treatment for not less than 3 months.

Exclusion Criteria:

  • Unwillingness to consent to study inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01359800

South Africa
Walter Sisulu University HIV Vaccine Research Unit
Mthatha, Eastern Cape, South Africa
Mecru Clinical Research Unit (MeCRU)
Medunsa, Gauteng, South Africa
Sponsors and Collaborators
Barbara Ensoli, MD
Italian Ministry of Foreign Affairs - Dir. Gen. for Cooperation and Development
Study Director: Barbara BE Ensoli, MD PhD Istituto Superiore di Sanità
  More Information

Additional Information:

Responsible Party: Barbara Ensoli, MD, PhD, Istituto Superiore di Sanità Identifier: NCT01359800     History of Changes
Other Study ID Numbers: ISS OBS T-004
Study First Received: May 17, 2011
Last Updated: March 3, 2016

Keywords provided by Istituto Superiore di Sanità:

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017